# Topic 2 :Fine-Tuning-Small-Language-Model-Sub-4-with-Higher-Language-Model
Fine-Tuning Small Language Model (Sub-4) with Higher Language Model ‚Äî Specific Task: Drug Interaction Analysis


### üìò Overview

‡πÇ‡∏õ‡∏£‡πÄ‡∏à‡∏Å‡∏ï‡πå‡∏ô‡∏µ‡πâ‡∏°‡∏µ‡∏à‡∏∏‡∏î‡∏õ‡∏£‡∏∞‡∏™‡∏á‡∏Ñ‡πå‡πÄ‡∏û‡∏∑‡πà‡∏≠ ‡∏û‡∏±‡∏í‡∏ô‡∏≤ Small Language Model (SLM) ‡∏ó‡∏µ‡πà‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏ó‡∏≥‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡πÅ‡∏•‡∏∞‡∏ß‡∏¥‡πÄ‡∏Ñ‡∏£‡∏≤‡∏∞‡∏´‡πå ‚Äú‡∏õ‡∏è‡∏¥‡∏Å‡∏¥‡∏£‡∏¥‡∏¢‡∏≤‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏¢‡∏≤ (Drug Interactions)‚Äù ‡πÑ‡∏î‡πâ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡πÅ‡∏°‡πà‡∏ô‡∏¢‡∏≥‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô
‡πÇ‡∏î‡∏¢‡πÉ‡∏ä‡πâ‡∏ß‡∏¥‡∏ò‡∏µ‡∏Å‡∏≤‡∏£ Fine-tuning ‡∏à‡∏≤‡∏Å‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏ê‡∏≤‡∏ô (Base Model) ‡∏î‡πâ‡∏ß‡∏¢‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡∏ó‡∏≤‡∏á‡∏î‡πâ‡∏≤‡∏ô‡πÄ‡∏†‡∏™‡∏±‡∏ä‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤ ‡∏û‡∏£‡πâ‡∏≠‡∏°‡∏Å‡∏≤‡∏£‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡∏£‡∏π‡πâ‡∏à‡∏≤‡∏Å ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ñ‡∏£‡∏π (Teacher Model) ‡∏ó‡∏µ‡πà‡∏°‡∏µ‡∏õ‡∏£‡∏∞‡∏™‡∏¥‡∏ó‡∏ò‡∏¥‡∏†‡∏≤‡∏û‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤

‡∏á‡∏≤‡∏ô‡∏ô‡∏µ‡πâ‡πÄ‡∏õ‡πá‡∏ô‡∏™‡πà‡∏ß‡∏ô‡∏´‡∏ô‡∏∂‡πà‡∏á‡∏Ç‡∏≠‡∏á‡πÅ‡∏ô‡∏ß‡∏ó‡∏≤‡∏á Knowledge Distillation + Fine-tuning
‡∏ó‡∏µ‡πà‡∏°‡∏∏‡πà‡∏á‡πÄ‡∏ô‡πâ‡∏ô‡πÉ‡∏´‡πâ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ç‡∏ô‡∏≤‡∏î‡πÄ‡∏•‡πá‡∏Å (Sub-4B parameters) ‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡∏£‡∏π‡πâ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏π‡πâ‡πÄ‡∏ä‡∏¥‡∏á‡∏•‡∏∂‡∏Å‡∏à‡∏≤‡∏Å‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ç‡∏ô‡∏≤‡∏î‡πÉ‡∏´‡∏ç‡πà
‡πÇ‡∏î‡∏¢‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô ‚Äú‡∏Å‡∏•‡πÑ‡∏Å‡∏Å‡∏≤‡∏£‡∏≠‡∏≠‡∏Å‡∏§‡∏ó‡∏ò‡∏¥‡πå‡∏Ç‡∏≠‡∏á‡∏¢‡∏≤ (Mechanism of Action, MOA)‚Äù
‡πÅ‡∏•‡∏∞ ‚Äú‡∏ú‡∏•‡∏Å‡∏£‡∏∞‡∏ó‡∏ö‡∏Ç‡∏≠‡∏á‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ô‚Äù

| üß© ‡∏≠‡∏á‡∏Ñ‡πå‡∏õ‡∏£‡∏∞‡∏Å‡∏≠‡∏ö            | üí° ‡∏£‡∏≤‡∏¢‡∏•‡∏∞‡πÄ‡∏≠‡∏µ‡∏¢‡∏î                                                                                                 |
| ------------------------ | ------------------------------------------------------------------------------------------------------------- |
| **Base Model (Student)** | `Qwen/Qwen3-1.7B` ‚Äî ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏†‡∏≤‡∏©‡∏≤‡πÄ‡∏ö‡∏≤‡∏Ç‡∏ô‡∏≤‡∏î‡∏¢‡πà‡∏≠‡∏° (<4B params) ‡∏ó‡∏µ‡πà‡∏£‡∏≠‡∏á‡∏£‡∏±‡∏ö instruction-following                         |
| **Teacher Model**        | `openai/gpt-4o-mini` ‚Äî ‡πÉ‡∏ä‡πâ‡∏ú‡πà‡∏≤‡∏ô **OpenRouter API**, ‡πÄ‡∏´‡∏ï‡∏∏‡∏ú‡∏•‡∏ó‡∏µ‡πà‡πÄ‡∏•‡∏∑‡∏≠‡∏Å: ‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÅ‡∏°‡πà‡∏ô‡∏¢‡∏≥‡πÄ‡∏ä‡∏¥‡∏á‡∏†‡∏≤‡∏©‡∏≤‡∏™‡∏π‡∏á‡πÅ‡∏ï‡πà‡∏£‡∏≤‡∏Ñ‡∏≤‡∏õ‡∏£‡∏∞‡∏´‡∏¢‡∏±‡∏î      |
| **Environment**          | Google Colab (GPU L4-100) ‡∏û‡∏£‡πâ‡∏≠‡∏° CUDA Runtime                                                                  |
| **Frameworks**           | Hugging Face Transformers, PEFT (LoRA), Datasets, OpenAI API                                                  |
| **Training Objective**   | ‡∏™‡∏≠‡∏ô‡πÉ‡∏´‡πâ student model ‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡πÇ‡∏Ñ‡∏£‡∏á‡∏™‡∏£‡πâ‡∏≤‡∏á‡πÄ‡∏ä‡∏¥‡∏á‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏π‡πâ‡∏ó‡∏≤‡∏á‡∏¢‡∏≤ ‡πÄ‡∏ä‡πà‡∏ô **drug‚Äìaction‚Äìtarget relationships**                |
| **Evaluation**           | ‡πÄ‡∏õ‡∏£‡∏µ‡∏¢‡∏ö‡πÄ‡∏ó‡∏µ‡∏¢‡∏ö‡∏ú‡∏•‡∏•‡∏±‡∏û‡∏ò‡πå‡∏Å‡∏±‡∏ö teacher model ‡∏ú‡πà‡∏≤‡∏ô‡∏´‡∏•‡∏≤‡∏¢‡∏°‡∏¥‡∏ï‡∏¥ ‡πÄ‡∏ä‡πà‡∏ô **F1**, **BLEU**, **Fact Triple Match**, **Perplexity** |

### üíä ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç‡∏Ç‡∏≠‡∏á‡∏á‡∏≤‡∏ô‡∏ß‡∏¥‡πÄ‡∏Ñ‡∏£‡∏≤‡∏∞‡∏´‡πå‡∏õ‡∏è‡∏¥‡∏Å‡∏¥‡∏£‡∏¥‡∏¢‡∏≤‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏¢‡∏≤ (Drug Interaction Analysis)

- Drug Interaction Analysis ‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏±‡∏ß‡πÉ‡∏à‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç‡∏Ç‡∏≠‡∏á‡∏Å‡∏≤‡∏£‡πÅ‡∏û‡∏ó‡∏¢‡πå‡πÄ‡∏ä‡∏¥‡∏á‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô (Preventive Medicine)
‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏õ‡∏è‡∏¥‡∏Å‡∏¥‡∏£‡∏¥‡∏¢‡∏≤‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏¢‡∏≤‡∏ö‡∏≤‡∏á‡∏ä‡∏ô‡∏¥‡∏î‡∏≠‡∏≤‡∏à‡∏™‡πà‡∏á‡∏ú‡∏•‡∏ï‡πà‡∏≠‡∏õ‡∏£‡∏∞‡∏™‡∏¥‡∏ó‡∏ò‡∏¥‡∏†‡∏≤‡∏û‡∏´‡∏£‡∏∑‡∏≠‡∏Å‡πà‡∏≠‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î‡∏≠‡∏±‡∏ô‡∏ï‡∏£‡∏≤‡∏¢‡∏ï‡πà‡∏≠‡∏ú‡∏π‡πâ‡∏õ‡πà‡∏ß‡∏¢ ‡πÄ‡∏ä‡πà‡∏ô

- ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡∏°‡∏µ‡∏ú‡∏•‡∏ï‡πà‡∏≠‡πÄ‡∏≠‡∏ô‡πÑ‡∏ã‡∏°‡πå CYP450 ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ô

- ‡∏Å‡∏≤‡∏£‡πÄ‡∏™‡∏£‡∏¥‡∏°‡∏§‡∏ó‡∏ò‡∏¥‡πå (synergistic) ‡∏´‡∏£‡∏∑‡∏≠‡∏´‡∏±‡∏Å‡∏•‡πâ‡∏≤‡∏á‡∏Å‡∏±‡∏ô (antagonistic) ‡∏Ç‡∏≠‡∏á‡∏¢‡∏≤

- ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏†‡∏≤‡∏©‡∏≤‡∏°‡∏≤‡∏ä‡πà‡∏ß‡∏¢ ‡∏ï‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÅ‡∏•‡∏∞‡∏™‡∏£‡∏∏‡∏õ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏™‡∏±‡∏°‡∏û‡∏±‡∏ô‡∏ò‡πå‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏¢‡∏≤
‡∏ä‡πà‡∏ß‡∏¢‡πÉ‡∏´‡πâ‡∏£‡∏∞‡∏ö‡∏ö‡∏™‡∏ô‡∏±‡∏ö‡∏™‡∏ô‡∏∏‡∏ô‡∏Å‡∏≤‡∏£‡∏ï‡∏±‡∏î‡∏™‡∏¥‡∏ô‡πÉ‡∏à‡∏ó‡∏≤‡∏á‡∏Ñ‡∏•‡∏¥‡∏ô‡∏¥‡∏Å
(Clinical Decision Support System: CDSS)
‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏Ñ‡∏±‡∏î‡∏Å‡∏£‡∏≠‡∏á‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ô‡πÑ‡∏î‡πâ ‡∏£‡∏ß‡∏î‡πÄ‡∏£‡πá‡∏ß‡πÅ‡∏•‡∏∞‡πÅ‡∏°‡πà‡∏ô‡∏¢‡∏≥‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô

### üß© ‡∏à‡∏∏‡∏î‡∏õ‡∏£‡∏∞‡∏™‡∏á‡∏Ñ‡πå‡∏Ç‡∏≠‡∏á‡πÇ‡∏Ñ‡∏£‡∏á‡∏Å‡∏≤‡∏£

1Ô∏è‚É£ ‡∏û‡∏±‡∏í‡∏ô‡∏≤‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏†‡∏≤‡∏©‡∏≤‡πÄ‡∏ö‡∏≤ (Small LM)
‡πÉ‡∏´‡πâ‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ ‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡∏Å‡∏•‡πÑ‡∏Å‡∏¢‡∏≤‡πÅ‡∏•‡∏∞‡∏õ‡∏è‡∏¥‡∏Å‡∏¥‡∏£‡∏¥‡∏¢‡∏≤‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏¢‡∏≤ ‡πÑ‡∏î‡πâ‡πÉ‡∏Å‡∏•‡πâ‡πÄ‡∏Ñ‡∏µ‡∏¢‡∏á‡∏Å‡∏±‡∏ö‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ç‡∏ô‡∏≤‡∏î‡πÉ‡∏´‡∏ç‡πà

2Ô∏è‚É£ ‡∏≠‡∏≠‡∏Å‡πÅ‡∏ö‡∏ö‡∏ß‡∏¥‡∏ò‡∏µ‡∏Å‡∏≤‡∏£ Fine-tuning
‡πÉ‡∏´‡πâ‡∏°‡∏µ‡∏õ‡∏£‡∏∞‡∏™‡∏¥‡∏ó‡∏ò‡∏¥‡∏†‡∏≤‡∏û‡∏™‡∏π‡∏á‡πÅ‡∏ï‡πà‡πÉ‡∏ä‡πâ ‡∏ó‡∏£‡∏±‡∏û‡∏¢‡∏≤‡∏Å‡∏£ GPU ‡∏à‡∏≥‡∏Å‡∏±‡∏î (Colab L4)

3Ô∏è‚É£ ‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏Å‡∏£‡∏≠‡∏ö‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏ú‡∏• (Evaluation Framework)
‡πÉ‡∏´‡πâ‡∏™‡∏∞‡∏ó‡πâ‡∏≠‡∏ô‡∏Ñ‡∏∏‡∏ì‡∏†‡∏≤‡∏û‡∏ó‡∏±‡πâ‡∏á‡πÄ‡∏ä‡∏¥‡∏á ‡∏†‡∏≤‡∏©‡∏≤‡∏®‡∏≤‡∏™‡∏ï‡∏£‡πå ‡πÅ‡∏•‡∏∞ ‡πÄ‡∏ô‡∏∑‡πâ‡∏≠‡∏´‡∏≤‡πÄ‡∏†‡∏™‡∏±‡∏ä‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤

4Ô∏è‚É£ ‡∏ó‡∏î‡∏™‡∏≠‡∏ö‡πÅ‡∏•‡∏∞‡∏ß‡∏¥‡πÄ‡∏Ñ‡∏£‡∏≤‡∏∞‡∏´‡πå‡πÇ‡∏°‡πÄ‡∏î‡∏•
‡πÄ‡∏õ‡∏£‡∏µ‡∏¢‡∏ö‡πÄ‡∏ó‡∏µ‡∏¢‡∏ö‡∏ú‡∏•‡∏•‡∏±‡∏û‡∏ò‡πå‡∏Ç‡∏≠‡∏á Base Model, Fine-tuned Model ‡πÅ‡∏•‡∏∞ Teacher Model
‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏ß‡∏¥‡πÄ‡∏Ñ‡∏£‡∏≤‡∏∞‡∏´‡πå‡πÄ‡∏ä‡∏¥‡∏á‡∏Ñ‡∏∏‡∏ì‡∏†‡∏≤‡∏û‡πÅ‡∏•‡∏∞‡πÄ‡∏ä‡∏¥‡∏á‡∏õ‡∏£‡∏¥‡∏°‡∏≤‡∏ì‡∏≠‡∏¢‡πà‡∏≤‡∏á‡πÄ‡∏õ‡πá‡∏ô‡∏£‡∏∞‡∏ö‡∏ö


### üìä Project Flow

```mermaid
flowchart LR
    A["Pharmacology Dataset<br/>(Drug Interaction & MOA)"] --> B["Tokenization & Preprocessing"]
    B --> C["Base Model: Qwen/Qwen3-1.7B"]
    C --> D["Fine-Tuning (LoRA + Teacher Guidance)"]
    D --> E["Evaluation: F1, BLEU, Fact Triple Match, Perplexity"]
    E --> F["Compare with Teacher (GPT-4o-mini)"]
    F --> G["Final Report & Analysis"]
```


### üß† Model Setup

‡πÉ‡∏ô‡∏á‡∏≤‡∏ô‡∏ô‡∏µ‡πâ‡πÉ‡∏ä‡πâ‡πÅ‡∏ô‡∏ß‡∏Ñ‡∏¥‡∏î ‚ÄúTeacher‚ÄìStudent Fine-Tuning‚Äù
‡πÇ‡∏î‡∏¢‡πÉ‡∏´‡πâ ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ñ‡∏£‡∏π (Teacher Model) ‡∏ã‡∏∂‡πà‡∏á‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ç‡∏ô‡∏≤‡∏î‡πÉ‡∏´‡∏ç‡πà‡πÅ‡∏•‡∏∞‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÅ‡∏°‡πà‡∏ô‡∏¢‡∏≥‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤
‡∏ä‡πà‡∏ß‡∏¢‡∏™‡∏£‡πâ‡∏≤‡∏á ‚Äú‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏Ñ‡∏∏‡∏ì‡∏†‡∏≤‡∏û‡∏™‡∏π‡∏á (High-quality Responses)‚Äù
‡πÄ‡∏û‡∏∑‡πà‡∏≠‡πÉ‡∏ä‡πâ‡πÄ‡∏õ‡πá‡∏ô ‚Äúlabel ‡∏ó‡∏µ‡πà‡∏™‡∏±‡∏á‡πÄ‡∏Ñ‡∏£‡∏≤‡∏∞‡∏´‡πå (Synthetic Supervision)‚Äù ‡∏™‡∏≥‡∏´‡∏£‡∏±‡∏ö‡∏Å‡∏≤‡∏£‡∏™‡∏≠‡∏ô ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏ô‡∏±‡∏Å‡πÄ‡∏£‡∏µ‡∏¢‡∏ô (Student Model)

| ‡∏õ‡∏£‡∏∞‡πÄ‡∏†‡∏ó‡πÇ‡∏°‡πÄ‡∏î‡∏•                 | ‡∏ä‡∏∑‡πà‡∏≠‡πÇ‡∏°‡πÄ‡∏î‡∏•                          | ‡∏à‡∏∏‡∏î‡πÄ‡∏î‡πà‡∏ô                                                                      | ‡∏ö‡∏ó‡∏ö‡∏≤‡∏ó‡πÉ‡∏ô‡∏£‡∏∞‡∏ö‡∏ö                                        |
| --------------------------- | ---------------------------------- | ---------------------------------------------------------------------------- | -------------------------------------------------- |
| üß© **Teacher Model**        | `openai/gpt-4o-mini`               | ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡πÄ‡∏ä‡∏¥‡∏á‡∏ö‡∏£‡∏¥‡∏ö‡∏ó‡∏™‡∏π‡∏á, ‡∏ï‡∏≠‡∏ö‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏°‡∏µ‡πÄ‡∏´‡∏ï‡∏∏‡∏ú‡∏•, ‡πÉ‡∏ä‡πâ‡∏á‡∏≤‡∏ô‡∏ú‡πà‡∏≤‡∏ô OpenRouter ‡∏£‡∏≤‡∏Ñ‡∏≤‡∏õ‡∏£‡∏∞‡∏´‡∏¢‡∏±‡∏î  | ‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏ï‡∏±‡∏ß‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏Ñ‡∏∏‡∏ì‡∏†‡∏≤‡∏û‡∏™‡∏π‡∏á‡πÄ‡∏û‡∏∑‡πà‡∏≠‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£ fine-tune |
| üí° **Base Model (Student)** | `Qwen/Qwen3-1.7B`                  | ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ç‡∏ô‡∏≤‡∏î‡∏¢‡πà‡∏≠‡∏° (Sub-4B), ‡∏£‡∏≠‡∏á‡∏£‡∏±‡∏ö instruction tuning, ‡∏õ‡∏£‡∏±‡∏ö‡∏à‡∏π‡∏ô‡πÑ‡∏î‡πâ‡∏ö‡∏ô Colab GPU L4 | ‡πÄ‡∏õ‡πá‡∏ô‡∏ê‡∏≤‡∏ô‡∏™‡∏≥‡∏´‡∏£‡∏±‡∏ö‡∏Å‡∏≤‡∏£‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡∏£‡∏π‡πâ‡∏à‡∏≤‡∏Å‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡πÄ‡∏†‡∏™‡∏±‡∏ä‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤        |
| üß† **Fine-tuned Model**     | `Qwen3-1.7B-Drug-Interaction-LoRA` | ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏ó‡∏µ‡πà‡∏ú‡πà‡∏≤‡∏ô‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏±‡∏ö‡∏à‡∏π‡∏ô‡∏î‡πâ‡∏ß‡∏¢‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡∏î‡πâ‡∏≤‡∏ô‡∏¢‡∏≤‡πÅ‡∏•‡∏∞‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏à‡∏≤‡∏Å Teacher               | ‡πÉ‡∏ä‡πâ‡∏ó‡∏î‡∏™‡∏≠‡∏ö‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡πÉ‡∏ô‡∏á‡∏≤‡∏ô Drug Interaction           |

### üß©Training Architecture

‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏±‡∏ö‡∏à‡∏π‡∏ô‡πÉ‡∏ä‡πâ‡πÄ‡∏ó‡∏Ñ‡∏ô‡∏¥‡∏Ñ LoRA (Low-Rank Adaptation)
‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏•‡∏î‡∏à‡∏≥‡∏ô‡∏ß‡∏ô‡∏û‡∏≤‡∏£‡∏≤‡∏°‡∏¥‡πÄ‡∏ï‡∏≠‡∏£‡πå‡∏ó‡∏µ‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏≠‡∏±‡∏õ‡πÄ‡∏î‡∏ï ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ fine-tune ‡∏ö‡∏ô GPU ‡∏Ç‡∏ô‡∏≤‡∏î‡∏Å‡∏•‡∏≤‡∏á (‡πÄ‡∏ä‡πà‡∏ô L4-100) ‡πÑ‡∏î‡πâ‡πÇ‡∏î‡∏¢‡πÑ‡∏°‡πà‡∏Å‡∏¥‡∏ô‡∏´‡∏ô‡πà‡∏ß‡∏¢‡∏Ñ‡∏ß‡∏≤‡∏°‡∏à‡∏≥‡∏°‡∏≤‡∏Å
‡∏Å‡∏≤‡∏£‡∏ù‡∏∂‡∏Å‡∏à‡∏∞‡∏≠‡πâ‡∏≤‡∏á‡∏≠‡∏¥‡∏á‡πÇ‡∏Ñ‡∏£‡∏á‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏î‡∏±‡∏á‡∏ô‡∏µ‡πâ üëá

```mermaid
flowchart TD
    A["Drug Interaction Dataset (Prompt‚ÄìAnswer Pairs)"] --> B["Teacher Model: GPT-4o-mini"]
    B --> C["Synthetic Responses"]
    C --> D["Base Model: Qwen/Qwen3-1.7B"]
    D --> E["LoRA Fine-Tuning on Colab GPU L4"]
    E --> F["Fine-Tuned Model: Qwen3-1.7B-Drug-Interaction-LoRA"]
    F --> G["Evaluation & Comparison"]
```

### üß© ‡∏Å‡∏≤‡∏£‡∏ï‡∏±‡πâ‡∏á‡∏Ñ‡πà‡∏≤ (Model & Training Configuration)

### üíª Environment

- üå©Ô∏è Platform: **Google Colab Pro**
- üíæ GPU: **NVIDIA L4 (24 GB VRAM)**
- üß© Frameworks: **Transformers**, **PEFT (LoRA)**, **Datasets**, **Torch**
- üì¶ Dataset format: `CSV ‚Üí Dataset.from_pandas(df)`
    
    ‡∏û‡∏£‡πâ‡∏≠‡∏°‡∏ü‡∏¥‡∏•‡∏î‡πå:
    
    - `prompt`: ‡∏Ñ‡∏≥‡∏ñ‡∏≤‡∏°‡∏´‡∏£‡∏∑‡∏≠‡∏ö‡∏£‡∏¥‡∏ö‡∏ó‡∏ó‡∏≤‡∏á‡∏¢‡∏≤
    - `response_teacher`: ‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏ó‡∏µ‡πà‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏à‡∏≤‡∏Å GPT-4o-mini
    - `response_student`: ‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏Ç‡∏≠‡∏á base model (‡πÉ‡∏ä‡πâ‡πÄ‡∏õ‡∏£‡∏µ‡∏¢‡∏ö‡πÄ‡∏ó‡∏µ‡∏¢‡∏ö‡∏Å‡πà‡∏≠‡∏ô‡πÅ‡∏•‡∏∞‡∏´‡∏•‡∏±‡∏á‡∏à‡∏π‡∏ô)

## üß© Code Walkthrough

### 1) Model Setup
   ```python
   MODEL_NAME = "Qwen/Qwen3-1.7B"
   TEACHER_MODEL = "openai/gpt-4o-mini"
   ```
- MODEL_NAME : ‡∏ä‡∏∑‡πà‡∏≠ ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏ô‡∏±‡∏Å‡πÄ‡∏£‡∏µ‡∏¢‡∏ô (Student/Base) ‡∏ó‡∏µ‡πà‡∏à‡∏∞‡∏ñ‡∏π‡∏Å fine-tune

- TEACHER_MODEL : ‡∏ä‡∏∑‡πà‡∏≠ ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ñ‡∏£‡∏π (Teacher) ‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏Ñ‡∏∏‡∏ì‡∏†‡∏≤‡∏û‡∏™‡∏π‡∏á (‡∏™‡∏≥‡∏´‡∏£‡∏±‡∏ö‡∏ó‡∏≥ dataset ‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏õ‡∏£‡∏µ‡∏¢‡∏ö‡πÄ‡∏ó‡∏µ‡∏¢‡∏ö‡∏†‡∏≤‡∏¢‡∏´‡∏•‡∏±‡∏á)

### 2) Config ‡∏ó‡∏±‡πà‡∏ß‡πÑ‡∏õ
   ```python
    MAX_LENGTH = 2048
    SEED = 42
    VAL_SIZE = 0.1
    EVAL_STRATEGY = "epoch"
    OUTPUT_DIR = "./finetuned_qwen_drug_lora"
   ```
- MAX_LENGTH=2048 : ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏¢‡∏≤‡∏ß‡πÇ‡∏ó‡πÄ‡∏Ñ‡∏ô‡∏™‡∏π‡∏á‡∏™‡∏∏‡∏î‡∏ï‡πà‡∏≠‡∏≠‡∏¥‡∏ô‡∏û‡∏∏‡∏ï+‡πÄ‡∏≠‡∏≤‡∏ï‡πå‡∏û‡∏∏‡∏ï (‡∏ï‡∏±‡∏î‡∏Ç‡πâ‡∏≠‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ñ‡πâ‡∏≤‡∏¢‡∏≤‡∏ß‡πÄ‡∏Å‡∏¥‡∏ô)

- SEED=42 : ‡∏Ñ‡πà‡∏≤‡∏ï‡∏±‡πâ‡∏á‡∏ï‡πâ‡∏ô‡∏™‡∏∏‡πà‡∏° ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏£‡∏±‡∏ô‡∏ã‡πâ‡∏≥‡πÑ‡∏î‡πâ‡∏ú‡∏•‡πÉ‡∏Å‡∏•‡πâ‡πÄ‡∏Ñ‡∏µ‡∏¢‡∏á‡πÄ‡∏î‡∏¥‡∏° (reproducibility)

- VAL_SIZE=0.1 : ‡πÅ‡∏ö‡πà‡∏á‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏• 10% ‡πÄ‡∏õ‡πá‡∏ô validation set

- EVAL_STRATEGY="epoch" : ‡πÉ‡∏´‡πâ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏ú‡∏•‡∏ó‡∏∏‡∏Å ‡∏´‡∏ô‡∏∂‡πà‡∏á epoch (‡∏≠‡∏µ‡∏Å‡∏ï‡∏±‡∏ß‡πÄ‡∏•‡∏∑‡∏≠‡∏Å‡∏Ñ‡∏∑‡∏≠ "steps")

- OUTPUT_DIR : ‡πÇ‡∏ü‡∏•‡πÄ‡∏î‡∏≠‡∏£‡πå‡πÄ‡∏Å‡πá‡∏ö checkpoint/‡∏ú‡∏•‡∏•‡∏±‡∏û‡∏ò‡πå‡∏Å‡∏≤‡∏£‡∏ù‡∏∂‡∏Å

### 3) LoRA Config
   ```python
    from peft import LoraConfig
    lora_config = LoraConfig(
    r=8,                     # low-rank dimension
    lora_alpha=32,           # scaling factor
    target_modules=["q_proj", "v_proj"],
    lora_dropout=0.05,
    bias="none",
    task_type="CAUSAL_LM"
   ```
- r=8 : ‡∏≠‡∏±‡∏ô‡∏î‡∏±‡∏ö‡∏ï‡πà‡∏≥ (rank) ‡∏Ç‡∏≠‡∏á‡πÄ‡∏°‡∏ó‡∏£‡∏¥‡∏Å‡∏ã‡πå LoRA ‚Äî ‡∏¢‡∏¥‡πà‡∏á‡∏°‡∏≤‡∏Å‡∏¢‡∏¥‡πà‡∏á‡∏°‡∏µ‡∏û‡∏≤‡∏£‡∏≤‡∏°‡∏¥‡πÄ‡∏ï‡∏≠‡∏£‡πå‡∏ó‡∏µ‡πà‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡∏£‡∏π‡πâ‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô (‡πÄ‡∏Å‡πà‡∏á‡∏Ç‡∏∂‡πâ‡∏ô ‡πÅ‡∏ï‡πà‡∏Å‡∏¥‡∏ô VRAM ‡πÄ‡∏û‡∏¥‡πà‡∏°)

- lora_alpha=32 : ‡∏ï‡∏±‡∏ß‡∏Ñ‡∏π‡∏ì (scaling) ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏õ‡∏£‡∏±‡∏ö‡∏™‡πÄ‡∏Å‡∏•‡∏≠‡∏±‡∏õ‡πÄ‡∏î‡∏ï‡∏Ç‡∏≠‡∏á LoRA

- target_modules=["q_proj", "v_proj"] : ‡πÄ‡∏•‡∏∑‡∏≠‡∏Å‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡πÄ‡∏•‡πÄ‡∏¢‡∏≠‡∏£‡πå‡∏ó‡∏µ‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏Å‡∏≤‡∏£‡∏â‡∏µ‡∏î LoRA (Q/V ‡πÇ‡∏õ‡∏£‡πÄ‡∏à‡∏Å‡∏ä‡∏±‡∏ô‡∏Ç‡∏≠‡∏á attention) ‚Üí ‡∏õ‡∏£‡∏∞‡∏´‡∏¢‡∏±‡∏î‡∏û‡∏•‡∏±‡∏á‡∏Ñ‡∏≥‡∏ô‡∏ß‡∏ì

- lora_dropout=0.05 : ‡∏ä‡πà‡∏ß‡∏¢‡∏Å‡∏±‡∏ô overfitting

- bias="none" : ‡πÑ‡∏°‡πà‡πÅ‡∏ï‡∏∞‡∏û‡∏≤‡∏£‡∏≤‡∏°‡∏¥‡πÄ‡∏ï‡∏≠‡∏£‡πå bias ‡∏Ç‡∏≠‡∏á‡πÇ‡∏°‡πÄ‡∏î‡∏•

- task_type="CAUSAL_LM" : ‡πÇ‡∏à‡∏ó‡∏¢‡πå‡πÄ‡∏õ‡πá‡∏ô‡∏Å‡∏≤‡∏£ generate ‡πÅ‡∏ö‡∏ö causal language modeling

### 4) Training Arguments
     ```python
    from transformers import TrainingArguments
    training_args = TrainingArguments(
    per_device_train_batch_size=2,
    gradient_accumulation_steps=4,
    num_train_epochs=3,
    learning_rate=2e-5,
    warmup_ratio=0.1,
    evaluation_strategy=EVAL_STRATEGY,
    logging_strategy="epoch",
    save_total_limit=2,
    output_dir=OUTPUT_DIR,
    fp16=True,
    ```


- per_device_train_batch_size=2 : batch ‡∏ï‡πà‡∏≠ GPU ‡∏´‡∏ô‡∏∂‡πà‡∏á‡∏ï‡∏±‡∏ß (‡∏™‡∏≥‡∏´‡∏£‡∏±‡∏ö L4 ‡∏°‡∏±‡∏Å‡πÄ‡∏£‡∏¥‡πà‡∏° 1‚Äì2)

- gradient_accumulation_steps=4 : ‡∏™‡∏∞‡∏™‡∏°‡∏Å‡∏£‡∏≤‡πÄ‡∏î‡∏µ‡∏¢‡∏ô‡∏ï‡πå 4 ‡∏Ñ‡∏£‡∏±‡πâ‡∏á‡∏Å‡πà‡∏≠‡∏ô‡∏≠‡∏±‡∏õ‡πÄ‡∏î‡∏ï‡∏´‡∏ô‡∏∂‡πà‡∏á‡∏™‡πÄ‡∏ï‡πá‡∏õ ‚Üí ‡πÄ‡∏ó‡∏µ‡∏¢‡∏ö‡πÄ‡∏ó‡πà‡∏≤ batch ‡∏£‡∏ß‡∏° = 2√ó4 = 8

- num_train_epochs=3 : ‡∏à‡∏≥‡∏ô‡∏ß‡∏ô‡∏£‡∏≠‡∏ö‡∏ù‡∏∂‡∏Å‡∏ó‡∏±‡πâ‡∏á‡∏ä‡∏∏‡∏î‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•

- learning_rate=2e-5 : ‡∏≠‡∏±‡∏ï‡∏£‡∏≤‡∏Å‡∏≤‡∏£‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡∏£‡∏π‡πâ (‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏ï‡πâ‡∏ô‡∏î‡∏µ‡∏™‡∏≥‡∏´‡∏£‡∏±‡∏ö LoRA/SLM)

- warmup_ratio=0.1 : 10% ‡πÅ‡∏£‡∏Å‡πÄ‡∏õ‡πá‡∏ô‡∏ä‡πà‡∏ß‡∏á‡∏ß‡∏≠‡∏£‡πå‡∏°‡∏≠‡∏±‡∏õ (LR ‡πÑ‡∏ï‡πà‡∏Ç‡∏∂‡πâ‡∏ô‡∏ä‡πâ‡∏≤‡πÜ ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡πÅ‡∏Å‡∏ß‡πà‡∏á)

- evaluation_strategy=EVAL_STRATEGY : ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏ú‡∏•‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏ù‡∏∂‡∏Å‡∏ï‡∏≤‡∏°‡∏ó‡∏µ‡πà‡∏ï‡∏±‡πâ‡∏á‡πÑ‡∏ß‡πâ (‡∏ó‡∏µ‡πà‡∏ô‡∏µ‡πà‡∏Ñ‡∏∑‡∏≠‡∏ó‡∏∏‡∏Å epoch)

- logging_strategy="epoch" : ‡∏ö‡∏±‡∏ô‡∏ó‡∏∂‡∏Å log ‡∏ó‡∏∏‡∏Å epoch (‡∏à‡∏∞‡πÉ‡∏ä‡πâ "steps" ‡∏Å‡πá‡πÑ‡∏î‡πâ‡∏ñ‡πâ‡∏≤‡∏≠‡∏¢‡∏≤‡∏Å‡∏î‡∏π‡∏•‡∏∞‡πÄ‡∏≠‡∏µ‡∏¢‡∏î‡∏Ç‡∏∂‡πâ‡∏ô)

- save_total_limit=2 : ‡πÄ‡∏Å‡πá‡∏ö checkpoint ‡∏•‡πà‡∏≤‡∏™‡∏∏‡∏î‡πÅ‡∏Ñ‡πà 2 ‡∏ä‡∏∏‡∏î (‡∏õ‡∏£‡∏∞‡∏´‡∏¢‡∏±‡∏î‡∏û‡∏∑‡πâ‡∏ô‡∏ó‡∏µ‡πà)

- output_dir=OUTPUT_DIR : ‡πÇ‡∏ü‡∏•‡πÄ‡∏î‡∏≠‡∏£‡πå‡∏ö‡∏±‡∏ô‡∏ó‡∏∂‡∏Å‡∏ú‡∏•

- fp16=True : ‡πÄ‡∏õ‡∏¥‡∏î mixed precision ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏ù‡∏∂‡∏Å‡πÄ‡∏£‡πá‡∏ß‡∏Ç‡∏∂‡πâ‡∏ô/‡∏Å‡∏¥‡∏ô VRAM ‡∏ô‡πâ‡∏≠‡∏¢‡∏•‡∏á (‡∏ñ‡πâ‡∏≤‡πÄ‡∏Ñ‡∏£‡∏∑‡πà‡∏≠‡∏á‡∏£‡∏≠‡∏á‡∏£‡∏±‡∏ö)

## Evaluate

‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡πÄ‡∏•‡∏∑‡∏≠‡∏Å‡∏´‡∏±‡∏ß‡∏Ç‡πâ‡∏≠‡∏ó‡∏µ‡πà2‡∏Ñ‡∏∑‡∏≠ ‡πÉ‡∏´‡πâ SLM ‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à/‡∏≠‡∏ò‡∏¥‡∏ö‡∏≤‡∏¢‡∏Å‡∏•‡πÑ‡∏Å‡∏¢‡∏≤‡πÅ‡∏•‡∏∞‡∏õ‡∏è‡∏¥‡∏Å‡∏¥‡∏£‡∏¥‡∏¢‡∏≤‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏¢‡∏≤ ‡πÑ‡∏î‡πâ‡πÉ‡∏Å‡∏•‡πâ‡πÄ‡∏Ñ‡∏µ‡∏¢‡∏á‡∏ú‡∏π‡πâ‡πÄ‡∏ä‡∏µ‡πà‡∏¢‡∏ß‡∏ä‡∏≤‡∏ç/Teacher ‡∏à‡∏∂‡∏á‡∏ï‡πâ‡∏≠‡∏á‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏ó‡∏±‡πâ‡∏á 3 ‡∏°‡∏¥‡∏ï‡∏¥:

### ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ñ‡∏π‡∏Å‡∏ï‡πâ‡∏≠‡∏á‡πÄ‡∏ä‡∏¥‡∏á‡∏†‡∏≤‡∏©‡∏≤/‡∏£‡∏π‡∏õ‡πÅ‡∏ö‡∏ö (Textual Quality)

- BLEU, ROUGE-L: ‡∏ß‡∏±‡∏î‡∏Ñ‡∏ß‡∏≤‡∏°‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢‡∏Å‡∏±‡∏ö‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏≠‡πâ‡∏≤‡∏á‡∏≠‡∏¥‡∏á‡πÉ‡∏ô‡πÄ‡∏ä‡∏¥‡∏á n-gram ‡πÅ‡∏•‡∏∞‡∏•‡∏≥‡∏î‡∏±‡∏ö‡∏Ç‡πâ‡∏≠‡∏Ñ‡∏ß‡∏≤‡∏°‡∏¢‡∏≤‡∏ß (LCS)
‚Üí ‡∏ñ‡πâ‡∏≤‡∏™‡∏π‡∏á ‡πÅ‡∏õ‡∏•‡∏ß‡πà‡∏≤‡πÇ‡∏Ñ‡∏£‡∏á/‡∏Ñ‡∏≥‡∏Ç‡∏≠‡∏á‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö ‚Äú‡∏ï‡∏£‡∏á‡πÅ‡∏ô‡∏ß‚Äù ‡∏Å‡∏±‡∏ö reference

### ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡πÄ‡∏ä‡∏¥‡∏á‡πÄ‡∏ô‡∏∑‡πâ‡∏≠‡∏´‡∏≤‡πÄ‡∏†‡∏™‡∏±‡∏ä‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤ (Domain Knowledge)

- MOA-Facet F1 (macro): ‡∏î‡∏∂‡∏á facet 3 ‡∏î‡πâ‡∏≤‡∏ô (target/action/pathway) ‡∏î‡πâ‡∏ß‡∏¢ lexicon + regex ‡πÅ‡∏•‡πâ‡∏ß‡∏Ñ‡∏≥‡∏ô‡∏ß‡∏ì F1

- Key-Term Coverage: ‡∏ï‡∏£‡∏ß‡∏à‡∏ß‡πà‡∏≤‡∏®‡∏±‡∏û‡∏ó‡πå‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç‡πÉ‡∏ô‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏≠‡πâ‡∏≤‡∏á‡∏≠‡∏¥‡∏á (‡πÄ‡∏ä‡πà‡∏ô CYP3A4, agonist, inhibitor) ‡∏ñ‡∏π‡∏Å ‚Äú‡∏Ñ‡∏£‡∏≠‡∏ö‡∏Ñ‡∏•‡∏∏‡∏°‚Äù ‡πÉ‡∏ô‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡πÇ‡∏°‡πÄ‡∏î‡∏•‡πÅ‡∏Ñ‡πà‡πÑ‡∏´‡∏ô

- Fact Triple Match (Exact/Soft): ‡∏™‡∏Å‡∏±‡∏î‡∏ó‡∏£‡∏¥‡πÄ‡∏õ‡∏¥‡∏• (Drug ‚Äì Action ‚Äì Target) ‡∏à‡∏≤‡∏Å‡∏Ç‡πâ‡∏≠‡∏Ñ‡∏ß‡∏≤‡∏° ‡πÅ‡∏•‡πâ‡∏ß‡πÄ‡∏ó‡∏µ‡∏¢‡∏ö‡∏Å‡∏±‡∏ö‡∏≠‡πâ‡∏≤‡∏á‡∏≠‡∏¥‡∏á
‚Üí ‡∏ñ‡πâ‡∏≤‡∏Ñ‡∏∞‡πÅ‡∏ô‡∏ô‡∏Å‡∏•‡∏∏‡πà‡∏°‡∏ô‡∏µ‡πâ‡∏™‡∏π‡∏á ‡πÅ‡∏õ‡∏•‡∏ß‡πà‡∏≤‡πÇ‡∏°‡πÄ‡∏î‡∏• ‚Äú‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡πÇ‡∏Ñ‡∏£‡∏á‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏π‡πâ‚Äù ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πà‡πÅ‡∏Ñ‡πà‡πÄ‡∏Ç‡∏µ‡∏¢‡∏ô‡∏™‡∏ß‡∏¢

### ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏•‡∏∑‡πà‡∏ô‡πÑ‡∏´‡∏•/‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏õ‡πá‡∏ô‡∏ò‡∏£‡∏£‡∏°‡∏ä‡∏≤‡∏ï‡∏¥ + ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÉ‡∏Å‡∏•‡πâ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏´‡∏°‡∏≤‡∏¢ (Fluency/Semantics)

- Perplexity (‡∏à‡∏≤‡∏Å eval_loss): ‡∏ï‡πà‡∏≥ = ‡∏†‡∏≤‡∏©‡∏≤‡∏•‡∏∑‡πà‡∏ô‡πÑ‡∏´‡∏•/‡∏Ñ‡∏≤‡∏î‡πÄ‡∏î‡∏≤‡πÑ‡∏î‡πâ

- BERTScore-F1 (‡πÄ‡∏•‡∏∑‡∏≠‡∏Å‡∏†‡∏≤‡∏©‡∏≤ th/en ‡∏≠‡∏±‡∏ï‡πÇ‡∏ô‡∏°‡∏±‡∏ï‡∏¥): ‡∏ß‡∏±‡∏î ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÉ‡∏Å‡∏•‡πâ‡πÄ‡∏Ñ‡∏µ‡∏¢‡∏á‡πÄ‡∏ä‡∏¥‡∏á‡∏Ñ‡∏ß‡∏≤‡∏°‡∏´‡∏°‡∏≤‡∏¢ ‡∏•‡∏∂‡∏Å‡∏Å‡∏ß‡πà‡∏≤ n-gram
‚Üí ‡∏ñ‡πâ‡∏≤‡∏™‡∏π‡∏á ‡πÅ‡∏õ‡∏•‡∏ß‡πà‡∏≤‡∏Ñ‡∏ß‡∏≤‡∏°‡∏´‡∏°‡∏≤‡∏¢‡πÇ‡∏î‡∏¢‡∏£‡∏ß‡∏°‡∏™‡∏≠‡∏î‡∏Ñ‡∏•‡πâ‡∏≠‡∏á ‡πÅ‡∏°‡πâ‡∏ñ‡πâ‡∏≠‡∏¢‡∏Ñ‡∏≥‡∏à‡∏∞‡∏ï‡πà‡∏≤‡∏á

### ‡∏Å‡∏≤‡∏£‡πÄ‡∏ó‡∏µ‡∏¢‡∏ö‡∏Å‡πà‡∏≠‡∏ô-‡∏´‡∏•‡∏±‡∏á‡∏à‡∏π‡∏ô‡πÅ‡∏ö‡∏ö‡πÉ‡∏ä‡πâ‡∏á‡∏≤‡∏ô‡∏à‡∏£‡∏¥‡∏á (Preference/Win-Rate)

- ‡πÉ‡∏ä‡πâ ROUGE-L-to-reference ‡∏ï‡πà‡∏≠‡πÇ‡∏à‡∏ó‡∏¢‡πå ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏´‡∏≤‡∏ß‡πà‡∏≤ FT ‡∏´‡∏£‡∏∑‡∏≠ Base ‡πÉ‡∏Å‡∏•‡πâ‡∏≠‡πâ‡∏≤‡∏á‡∏≠‡∏¥‡∏á‡∏Å‡∏ß‡πà‡∏≤

- ‡∏™‡∏£‡∏∏‡∏õ‡πÄ‡∏õ‡πá‡∏ô Win-rate@N: ‡∏î‡∏π‡∏ß‡πà‡∏≤‡∏à‡∏≤‡∏Å N ‡∏Ç‡πâ‡∏≠ FT ‡∏ä‡∏ô‡∏∞‡∏Å‡∏µ‡πà‡∏Ç‡πâ‡∏≠
‚Üí ‡πÉ‡∏´‡πâ‡∏†‡∏≤‡∏û ‚Äú‡∏õ‡∏£‡∏∞‡∏™‡∏¥‡∏ó‡∏ò‡∏¥‡∏†‡∏≤‡∏û‡∏à‡∏£‡∏¥‡∏á‡πÉ‡∏ô‡∏á‡∏≤‡∏ô‚Äù ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ metric ‡πÄ‡∏î‡∏µ‡πà‡∏¢‡∏ß

### Pipeline Evaluate


```mermaid
flowchart TD
    A["Trainer logs"] -->|extract| B["Train/Eval Loss ‚Üí PPL"]
    C["df_val"] --> D["Predict with model.generate"]

    D --> E["Textual Metrics: BLEU / ROUGE-L"]
    D --> F["Domain Metrics: Facet F1 ‚Ä¢ Key Terms ‚Ä¢ Triple"]
    D --> G["BERTScore (auto th/en)"]

    E --> H["metrics_val_TIMESTAMP.csv"]
    F --> H
    G --> H

    C --> I["Sample N rows"]
    I --> J["Base vs FT outputs"]
    J --> K["ROUGE-L to Ref ‚Üí Winner per item"]
    K --> L["Win-rate@N ‚Ä¢ Examples"]
    L --> M["evaluateTeacherStudent.csv"]

```

### ‡∏™‡∏¥‡πà‡∏á‡∏ó‡∏µ‡πà‡∏™‡∏Ñ‡∏£‡∏¥‡∏õ‡∏ï‡πå‡∏ó‡∏≥‡∏à‡∏£‡∏¥‡∏á (‡πÑ‡∏Æ‡πÑ‡∏•‡∏ó‡πå‡∏à‡∏≤‡∏Å‡πÇ‡∏Ñ‡πâ‡∏î)

- ‡∏î‡∏∂‡∏á Train/Eval loss ‡∏à‡∏≤‡∏Å trainer.state.log_history (‡∏ñ‡πâ‡∏≤‡∏°‡∏µ) ‚Üí ‡πÄ‡∏ã‡∏ü LOG_CSV ‡πÅ‡∏•‡∏∞‡∏Ñ‡∏≥‡∏ô‡∏ß‡∏ì Perplexity = exp(eval_loss)

- ‡∏£‡∏≠‡∏á‡∏£‡∏±‡∏ö‡∏Å‡∏£‡∏ì‡∏µ‡πÑ‡∏°‡πà‡∏°‡∏µ trainer.evaluate ‚Üí ‡πÅ‡∏™‡∏î‡∏á‡πÄ‡∏ï‡∏∑‡∏≠‡∏ô‡πÅ‡∏•‡πâ‡∏ß‡∏Ç‡πâ‡∏≤‡∏° (‡πÑ‡∏°‡πà‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡∏™‡∏Ñ‡∏£‡∏¥‡∏õ‡∏ï‡πå‡∏•‡πâ‡∏°)

- ‡πÇ‡∏´‡∏•‡∏î/‡πÄ‡∏ï‡∏£‡∏µ‡∏¢‡∏° df_val ‡∏≠‡∏±‡∏ï‡πÇ‡∏ô‡∏°‡∏±‡∏ï‡∏¥: ‡∏Ñ‡πâ‡∏ô‡∏´‡∏≤‡πÑ‡∏ü‡∏•‡πå val*.csv/parquet ‡∏ï‡∏≤‡∏°‡∏û‡∏≤‡∏ò‡∏°‡∏≤‡∏ï‡∏£‡∏ê‡∏≤‡∏ô, ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡πÄ‡∏à‡∏≠‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏ï‡∏±‡∏ß‡∏≠‡∏¢‡πà‡∏≤‡∏á 3‚Äì20 ‡πÅ‡∏ñ‡∏ß

- ‡∏™‡∏≥‡∏£‡∏≠‡∏á build_prompt(row): ‡∏ñ‡πâ‡∏≤‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏Ç‡∏≠‡∏á‡∏à‡∏£‡∏¥‡∏á ‡∏à‡∏∞‡∏î‡∏∂‡∏á‡∏à‡∏≤‡∏Å instruction/input/question

- ‡∏Ñ‡∏≥‡∏ô‡∏ß‡∏ì‡πÄ‡∏°‡∏ï‡∏£‡∏¥‡∏Å‡∏≠‡∏±‡∏ï‡πÇ‡∏ô‡∏°‡∏±‡∏ï‡∏¥ ‡∏ö‡∏ô validation

  - BLEU (NLTK) + smoothing

  - ROUGE-L (rouge_score)

  - MOA-Facet F1 (macro) ‡∏à‡∏≤‡∏Å regex lexicon (target/action/pathway)

  - Key-Term Coverage ‡∏à‡∏≤‡∏Å‡∏•‡∏¥‡∏™‡∏ï‡πå‡∏Ñ‡∏≥‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç

  - Triple Match ‡∏à‡∏≤‡∏Å‡πÅ‡∏û‡∏ï‡πÄ‡∏ó‡∏¥‡∏£‡πå‡∏ô (Drug ‚Äì Action ‚Äì Target) ‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏£‡∏¥‡∏¢‡∏≤‡πÇ‡∏î‡πÄ‡∏°‡∏ô (e.g., inhibits, antagonizes ‚Ä¶)

  - BERTScore-F1 (‡πÄ‡∏•‡∏∑‡∏≠‡∏Å‡∏†‡∏≤‡∏©‡∏≤ th ‡πÄ‡∏°‡∏∑‡πà‡∏≠‡∏Ç‡πâ‡∏≠‡∏Ñ‡∏ß‡∏≤‡∏°‡πÑ‡∏ó‡∏¢‡πÄ‡∏Å‡∏¥‡∏ô‡∏Ñ‡∏£‡∏∂‡πà‡∏á, ‡πÑ‡∏°‡πà‡∏á‡∏±‡πâ‡∏ô en, ‡πÅ‡∏•‡∏∞‡∏õ‡∏£‡∏±‡∏ö rescale_with_baseline)

- ‡πÄ‡∏ã‡∏ü‡∏ú‡∏•‡∏£‡∏ß‡∏°‡∏£‡∏≤‡∏¢‡∏Å‡∏≤‡∏£ ‚Üí metrics_val_YYYYMMDD_HHMMSS.csv (‡∏°‡∏µ prediction, reference ‡πÅ‡∏•‡∏∞‡∏ó‡∏∏‡∏Å metric ‡∏ï‡πà‡∏≠‡πÅ‡∏ñ‡∏ß)

- ‡∏ó‡∏≥ Pairwise Compare ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á Base ‡πÅ‡∏•‡∏∞ Fine-tuned

  - ‡∏™‡∏∏‡πà‡∏° N ‚â§ 20 ‡∏ï‡∏±‡∏ß‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å df_val

  - ‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏à‡∏≤‡∏Å Base ‡πÅ‡∏•‡∏∞ FT ‚Üí ‡∏ß‡∏±‡∏î ROUGE-L-to-Ref ‡∏£‡∏≤‡∏¢‡∏Ç‡πâ‡∏≠

  - ‡∏ï‡∏±‡∏î‡∏™‡∏¥‡∏ô‡∏ú‡∏π‡πâ‡∏ä‡∏ô‡∏∞ (FT/BASE/TIE) ‡πÅ‡∏•‡∏∞‡∏™‡∏£‡∏∏‡∏õ Win-rate@N

  - ‡πÄ‡∏ã‡∏ü‡∏™‡∏£‡∏∏‡∏õ + ‡∏Ñ‡πà‡∏≤‡πÄ‡∏â‡∏•‡∏µ‡πà‡∏¢‡πÄ‡∏°‡∏ï‡∏£‡∏¥‡∏Å‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç ‚Üí evaluateTeacherStudent.csv

  - ‡∏ñ‡πâ‡∏≤‡∏°‡∏µ‡πÑ‡∏ü‡∏•‡πå‡πÄ‡∏î‡∏¥‡∏° ‡∏à‡∏∞ ‡∏≠‡πà‡∏≤‡∏ô‡πÅ‡∏Ñ‡∏ä ‡πÅ‡∏•‡∏∞‡∏™‡∏£‡∏∏‡∏õ‡∏ú‡∏•‡πÉ‡∏´‡πâ‡πÇ‡∏î‡∏¢‡πÑ‡∏°‡πà‡∏£‡∏±‡∏ô‡πÉ‡∏´‡∏°‡πà (‡∏ï‡∏±‡πâ‡∏á FORCE_RERUN*_ ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏ö‡∏±‡∏á‡∏Ñ‡∏±‡∏ö‡∏£‡∏±‡∏ô)

### ‡∏ß‡∏¥‡∏ò‡∏µ‡∏≠‡πà‡∏≤‡∏ô‡∏ú‡∏• (Interpretation)

- Loss/PPL: ‡∏•‡∏î‡∏•‡∏á ‚Üí ‡∏†‡∏≤‡∏©‡∏≤‡∏•‡∏∑‡πà‡∏ô‡∏Ç‡∏∂‡πâ‡∏ô/‡πÇ‡∏°‡πÄ‡∏î‡∏• ‚Äú‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡∏£‡∏π‡πâ‚Äù ‡∏à‡∏£‡∏¥‡∏á ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤ eval_loss ‚â´ train_loss ‡∏≠‡∏≤‡∏à overfit

- BLEU/ROUGE-L: ‡∏™‡∏π‡∏á‡∏Ç‡∏∂‡πâ‡∏ô ‚Üí ‡∏™‡πÑ‡∏ï‡∏•‡πå/‡πÇ‡∏Ñ‡∏£‡∏á‡∏ï‡∏≠‡∏ö ‡πÉ‡∏Å‡∏•‡πâ‡∏≠‡πâ‡∏≤‡∏á‡∏≠‡∏¥‡∏á ‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô

- Facet F1 / Key-Term / Triple: ‡∏™‡∏π‡∏á‡∏Ç‡∏∂‡πâ‡∏ô ‚Üí ‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡∏Å‡∏•‡πÑ‡∏Å‡πÅ‡∏•‡∏∞‡πÇ‡∏Ñ‡∏£‡∏á‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏π‡πâ ‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô (‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î‡∏™‡∏≥‡∏´‡∏£‡∏±‡∏ö‡∏á‡∏≤‡∏ô MOA/Drug)

- BERTScore-F1: ‡∏™‡∏π‡∏á ‚Üí ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏´‡∏°‡∏≤‡∏¢‡πÇ‡∏î‡∏¢‡∏£‡∏ß‡∏° (semantic) ‡πÉ‡∏Å‡∏•‡πâ‡∏Å‡∏±‡∏ö reference

- Win-rate@N: ‡πÉ‡∏ä‡πâ‡∏á‡∏≤‡∏ô‡∏à‡∏£‡∏¥‡∏á‡πÑ‡∏î‡πâ‡∏á‡πà‡∏≤‡∏¢ ‚Üí ‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤ FT ‡∏ä‡∏ô‡∏∞ Base ‡∏Å‡∏µ‡πà‡πÄ‡∏õ‡∏≠‡∏£‡πå‡πÄ‡∏ã‡πá‡∏ô‡∏ï‡πå‡∏ö‡∏ô‡∏ä‡∏∏‡∏î‡πÇ‡∏à‡∏ó‡∏¢‡πå‡∏™‡∏±‡πâ‡∏ô‡πÜ

### ‡∏™‡∏£‡∏∏‡∏õ‡∏ú‡∏•

## Pairwise (Base vs FT)
‡∏™‡∏£‡∏∏‡∏õ‡∏à‡∏≤‡∏Å‡∏ú‡∏•‡∏£‡∏±‡∏ô‡∏ó‡∏î‡∏•‡∏≠‡∏á‡∏à‡∏£‡∏¥‡∏á (‡πÑ‡∏ü‡∏•‡πå‡πÅ‡∏Ñ‡∏ä): /content/drive/MyDrive/demo_finetuning/winrate_20.csv

‚ö†Ô∏è No training logs found ‚Üí ‡πÑ‡∏°‡πà‡∏°‡∏µ train/eval_loss ‡∏à‡∏∂‡∏á ‡πÑ‡∏°‡πà‡∏°‡∏µ Perplexity ‡∏£‡∏≠‡∏ö‡∏ô‡∏µ‡πâ

Win-rate@20 (FT vs BASE): 85.0% ‚Üí FT ‡∏ä‡∏ô‡∏∞ 17/20 ‡∏Ç‡πâ‡∏≠ (Base 3, Tie 0)

### ‡∏ß‡∏¥‡∏ò‡∏µ‡∏ß‡∏±‡∏î

- ‡πÄ‡∏•‡∏∑‡∏≠‡∏Å‡∏ï‡∏±‡∏ß‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏™‡∏π‡∏á‡∏™‡∏∏‡∏î 20 ‡∏Ç‡πâ‡∏≠‡∏à‡∏≤‡∏Å df_val (‡∏™‡∏∏‡πà‡∏°‡∏î‡πâ‡∏ß‡∏¢ SEED)

- ‡πÉ‡∏´‡πâ Base ‡πÅ‡∏•‡∏∞ Fine-tuned (FT) ‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡πÅ‡∏ö‡∏ö deterministic (do_sample=False)

- ‡∏Ñ‡∏≥‡∏ô‡∏ß‡∏ì ROUGE-L-to-Reference ‡∏ï‡πà‡∏≠‡∏Ç‡πâ‡∏≠: base_score_rougeL, ft_score_rougeL

- ‡∏ï‡∏±‡∏î‡∏™‡∏¥‡∏ô‡∏ú‡∏π‡πâ‡∏ä‡∏ô‡∏∞‡∏£‡∏≤‡∏¢‡∏Ç‡πâ‡∏≠: ‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤‡∏ä‡∏ô‡∏∞ ‚Üí winner ‚àà {FT, BASE, TIE}

- ‡∏£‡∏ß‡∏°‡∏ú‡∏•‡πÄ‡∏õ‡πá‡∏ô winrate_20.csv ‡πÅ‡∏•‡∏∞‡∏û‡∏¥‡∏°‡∏û‡πå‡∏™‡∏£‡∏∏‡∏õ Win-rate

```mermaid
pie showData
    title Win Split: FT vs Base (N=20)
    "FT wins" : 17
    "Base wins" : 3
    "Ties" : 0
```

| idx | instruction (‡∏ï‡∏±‡∏î‡∏¢‡πà‡∏≠)                                               | base_score_rougeL | ft_score_rougeL | winner |
| --: | ------------------------------------------------------------------ | ----------------: | --------------: | :----- |
|   0 | Explain the drug‚Äìdrug interaction between Docetaxel and Docetaxel‚Ä¶ |            0.1333 |      **0.2108** | FT     |
|   1 | Normalize ‚Ä¶ Augmentin 625 Duo Tablet into JSON‚Ä¶                    |            0.2210 |      **0.7041** | FT     |
|   2 | Translate the mechanism of action of Avastin 400mg‚Ä¶                |            0.0632 |      **0.0845** | FT     |
|   3 | Create a concise clinical card for Aciloc 150 Tablet‚Ä¶              |            0.2941 |      **0.7100** | FT     |
|   4 | Create a concise clinical card for Augmentin 625 Duo Tablet‚Ä¶       |            0.2426 |      **0.3534** | FT     |

## Automatic Metrics (Validation)

‡πÉ‡∏ô‡∏Ç‡∏±‡πâ‡∏ô‡∏ï‡∏≠‡∏ô‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô (Evaluation) ‡∏´‡∏•‡∏±‡∏á‡∏Å‡∏≤‡∏£ Fine-tuning
‡πÑ‡∏î‡πâ‡∏ó‡∏≥‡∏Å‡∏≤‡∏£‡∏ß‡∏±‡∏î‡∏ú‡∏•‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏î‡πâ‡∏ß‡∏¢ ‡πÄ‡∏°‡∏ï‡∏£‡∏¥‡∏Å‡∏´‡∏•‡∏≤‡∏Å‡∏´‡∏•‡∏≤‡∏¢‡∏î‡πâ‡∏≤‡∏ô ‡∏ó‡∏±‡πâ‡∏á‡∏ó‡∏≤‡∏á‡∏†‡∏≤‡∏©‡∏≤‡∏®‡∏≤‡∏™‡∏ï‡∏£‡πå‡πÅ‡∏•‡∏∞‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏π‡πâ‡πÄ‡∏ä‡∏¥‡∏á‡πÄ‡∏†‡∏™‡∏±‡∏ä‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤
‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏™‡∏∞‡∏ó‡πâ‡∏≠‡∏ô‡∏Ñ‡∏∏‡∏ì‡∏†‡∏≤‡∏û‡∏Ç‡∏≠‡∏á‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏ó‡∏µ‡πà‡∏ú‡πà‡∏≤‡∏ô‡∏Å‡∏≤‡∏£‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡∏£‡∏π‡πâ‡∏à‡∏≤‡∏Å‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏• Drug Interaction & Mechanism of Action (MOA)

### üéØ ‡πÄ‡∏´‡∏ï‡∏∏‡∏ú‡∏•‡∏ó‡∏µ‡πà‡πÄ‡∏•‡∏∑‡∏≠‡∏Å‡πÉ‡∏ä‡πâ Metric ‡πÄ‡∏´‡∏•‡πà‡∏≤‡∏ô‡∏µ‡πâ

| Metric                             | ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏´‡∏°‡∏≤‡∏¢                                                         | ‡πÄ‡∏´‡∏ï‡∏∏‡∏ú‡∏•‡∏ó‡∏µ‡πà‡πÄ‡∏•‡∏∑‡∏≠‡∏Å‡πÉ‡∏ä‡πâ                                |
| ---------------------------------- | ---------------------------------------------------------------- | ------------------------------------------------ |
| **BLEU / ROUGE-L**                 | ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÉ‡∏Å‡∏•‡πâ‡πÄ‡∏Ñ‡∏µ‡∏¢‡∏á‡∏Å‡∏±‡∏ö‡∏Ç‡πâ‡∏≠‡∏Ñ‡∏ß‡∏≤‡∏°‡∏≠‡πâ‡∏≤‡∏á‡∏≠‡∏¥‡∏á (n-gram overlap ‡πÅ‡∏•‡∏∞ LCS)          | ‡πÉ‡∏ä‡πâ‡∏ß‡∏±‡∏î‡∏Ñ‡∏∏‡∏ì‡∏†‡∏≤‡∏û‡∏Å‡∏≤‡∏£‡πÄ‡∏Ç‡∏µ‡∏¢‡∏ô‡πÅ‡∏•‡∏∞‡πÇ‡∏Ñ‡∏£‡∏á‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏†‡∏≤‡∏©‡∏≤‡∏Ç‡∏≠‡∏á‡∏ú‡∏•‡∏•‡∏±‡∏û‡∏ò‡πå   |
| **Facet F1 (macro)**               | Precision‚ÄìRecall ‡πÄ‡∏â‡∏•‡∏µ‡πà‡∏¢‡∏Ç‡∏≠‡∏á‡∏≠‡∏á‡∏Ñ‡πå‡∏õ‡∏£‡∏∞‡∏Å‡∏≠‡∏ö ‚ÄúTarget / Action / Pathway‚Äù | ‡∏ï‡∏£‡∏ß‡∏à‡∏™‡∏≠‡∏ö‡∏ß‡πà‡∏≤‡∏£‡∏∞‡∏ö‡∏∏‡∏≠‡∏á‡∏Ñ‡πå‡∏Ñ‡∏ß‡∏≤‡∏°‡∏£‡∏π‡πâ‡πÄ‡∏†‡∏™‡∏±‡∏ä‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤‡∏ñ‡∏π‡∏Å‡∏Ñ‡∏£‡∏ö‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà |
| **Key-Term Coverage**              | ‡∏≠‡∏±‡∏ï‡∏£‡∏≤‡∏Å‡∏≤‡∏£‡∏û‡∏ö‡∏Ñ‡∏≥‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç ‡πÄ‡∏ä‡πà‡∏ô ‚ÄúCYP3A4‚Äù, ‚Äúinhibitor‚Äù                     | ‡∏ß‡∏±‡∏î factual correctness ‡πÄ‡∏ä‡∏¥‡∏á‡∏Ñ‡∏≥‡∏®‡∏±‡∏û‡∏ó‡πå‡∏ó‡∏≤‡∏á‡∏¢‡∏≤         |
| **Fact Triple Match (Exact/Soft)** | ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÅ‡∏°‡πà‡∏ô‡∏¢‡∏≥‡πÇ‡∏Ñ‡∏£‡∏á‡∏™‡∏£‡πâ‡∏≤‡∏á ‚ÄúDrug‚ÄìAction‚ÄìTarget‚Äù                         | ‡∏ï‡∏£‡∏ß‡∏à‡∏™‡∏≠‡∏ö‡∏Å‡∏≤‡∏£‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡∏Å‡∏•‡πÑ‡∏Å‡πÄ‡∏ä‡∏¥‡∏á‡πÄ‡∏´‡∏ï‡∏∏‡∏ú‡∏•‡∏Ç‡∏≠‡∏á‡πÇ‡∏°‡πÄ‡∏î‡∏•           |
| **BERTScore (F1)**                 | ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÉ‡∏Å‡∏•‡πâ‡πÄ‡∏Ñ‡∏µ‡∏¢‡∏á‡πÄ‡∏ä‡∏¥‡∏á‡∏Ñ‡∏ß‡∏≤‡∏°‡∏´‡∏°‡∏≤‡∏¢‡πÅ‡∏ö‡∏ö contextual                          | ‡πÉ‡∏ä‡πâ LLM ‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô semantic similarity ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö |
| **Perplexity (PPL)**               | ‡∏Ñ‡∏ß‡∏≤‡∏°‡∏•‡∏∑‡πà‡∏ô‡πÑ‡∏´‡∏•‡∏Ç‡∏≠‡∏á‡∏†‡∏≤‡∏©‡∏≤‡∏à‡∏≤‡∏Å eval loss                                  | ‡πÉ‡∏ä‡πâ‡∏ß‡∏±‡∏î‡∏Ñ‡∏ß‡∏≤‡∏°‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏ó‡∏≤‡∏á‡∏†‡∏≤‡∏©‡∏≤‡∏Ç‡∏≠‡∏á‡πÇ‡∏°‡πÄ‡∏î‡∏•                  |

### üìà ‡∏ú‡∏•‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô (Validation Metrics)

| Metric                  | ‡∏Ñ‡πà‡∏≤‡πÄ‡∏â‡∏•‡∏µ‡πà‡∏¢‡∏ó‡∏µ‡πà‡πÑ‡∏î‡πâ   | ‡∏Å‡∏≤‡∏£‡∏ï‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°                                              |
| ----------------------- | ----------------- | ------------------------------------------------------ |
| **Eval Loss / PPL**     | `nan / nan`       | ‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏Ñ‡πà‡∏≤‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏à‡∏≤‡∏Å Trainer ‡πÑ‡∏°‡πà‡∏ñ‡∏π‡∏Å‡πÄ‡∏£‡∏µ‡∏¢‡∏Å evaluate ‡πÇ‡∏î‡∏¢‡∏ï‡∏£‡∏á  |
| **BLEU**                | `0.0097`          | ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏¢‡∏±‡∏á‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏õ‡∏£‡∏∞‡πÇ‡∏¢‡∏Ñ‡πÅ‡∏ï‡∏Å‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å reference ‡∏°‡∏≤‡∏Å            |
| **ROUGE-L**             | `0.1060`          | ‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏Ñ‡∏£‡∏≠‡∏ö‡∏Ñ‡∏•‡∏∏‡∏°‡∏ö‡∏≤‡∏á‡∏™‡πà‡∏ß‡∏ô‡∏Ç‡∏≠‡∏á‡∏™‡∏≤‡∏£‡∏∞‡∏à‡∏≤‡∏Å‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏≠‡πâ‡∏≤‡∏á‡∏≠‡∏¥‡∏á             |
| **Facet F1 (macro)**    | `0.1861`          | ‡∏£‡∏∞‡∏ö‡∏∏‡∏≠‡∏á‡∏Ñ‡πå‡∏õ‡∏£‡∏∞‡∏Å‡∏≠‡∏ö target/action/pathway ‡πÑ‡∏î‡πâ‡∏£‡∏∞‡∏î‡∏±‡∏ö‡πÄ‡∏ö‡∏∑‡πâ‡∏≠‡∏á‡∏ï‡πâ‡∏ô |
| **Key-Term Coverage**   | `0.8500`          | ‡∏Ñ‡∏£‡∏≠‡∏ö‡∏Ñ‡∏•‡∏∏‡∏°‡∏Ñ‡∏≥‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç‡∏ó‡∏≤‡∏á‡∏¢‡∏≤‡πÄ‡∏Å‡∏∑‡∏≠‡∏ö‡∏Ñ‡∏£‡∏ö (‡πÄ‡∏ä‡πà‡∏ô COX, ACE, receptor) |
| **Triple Exact / Soft** | `0.0500 / 0.0500` | ‡πÇ‡∏Ñ‡∏£‡∏á‡∏™‡∏£‡πâ‡∏≤‡∏á Drug‚ÄìAction‚ÄìTarget ‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡πÅ‡∏°‡πà‡∏ô‡∏¢‡∏≥              |
| **BERTScore (F1)**      | `0.8381`          | ‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡∏Ñ‡∏ß‡∏≤‡∏°‡∏´‡∏°‡∏≤‡∏¢‡πÉ‡∏Å‡∏•‡πâ‡πÄ‡∏Ñ‡∏µ‡∏¢‡∏á‡∏Å‡∏±‡∏ö reference ‡πÅ‡∏°‡πâ‡∏Ñ‡∏≥‡∏ï‡πà‡∏≤‡∏á‡∏Å‡∏±‡∏ô‡∏°‡∏≤‡∏Å   |

### üß™ Preference Test (Teacher vs Student)
‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡πÄ‡∏õ‡∏£‡∏µ‡∏¢‡∏ö‡πÄ‡∏ó‡∏µ‡∏¢‡∏ö‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏Ç‡∏≠‡∏á‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏ó‡∏µ‡πà‡∏ú‡πà‡∏≤‡∏ô Fine-tune (Student)
‡∏Å‡∏±‡∏ö‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ñ‡∏£‡∏π (Teacher = GPT-4o-mini) ‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£‡∏ß‡∏±‡∏î ROUGE-L-to-Reference
‡∏û‡∏ö‡∏ß‡πà‡∏≤:

| ‡∏ú‡∏•‡∏•‡∏±‡∏û‡∏ò‡πå         | ‡∏à‡∏≥‡∏ô‡∏ß‡∏ô | ‡∏™‡∏±‡∏î‡∏™‡πà‡∏ß‡∏ô (%) |
| --------------- | ----- | ----------- |
| üß† Teacher Wins | 20    | **100.0%**  |
| üéì Student Wins | 0     | 0.0%        |
| ‚öñÔ∏è Ties         | 0     | 0.0%        |

‡∏™‡∏£‡∏∏‡∏õ: ‡πÇ‡∏°‡πÄ‡∏î‡∏• Student ‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡πÅ‡∏Ç‡πà‡∏á‡∏Ç‡∏±‡∏ô‡∏Å‡∏±‡∏ö Teacher ‡πÑ‡∏î‡πâ
‡πÇ‡∏î‡∏¢ Teacher ‡∏°‡∏µ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÅ‡∏°‡πà‡∏ô‡∏¢‡∏≥‡∏ó‡∏≤‡∏á‡∏Å‡∏≤‡∏£‡πÅ‡∏û‡∏ó‡∏¢‡πå‡πÅ‡∏•‡∏∞‡πÇ‡∏Ñ‡∏£‡∏á‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏†‡∏≤‡∏©‡∏≤‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏ä‡∏±‡∏î‡πÄ‡∏à‡∏ô

### üìò ‡∏ï‡∏±‡∏ß‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡πÄ‡∏õ‡∏£‡∏µ‡∏¢‡∏ö‡πÄ‡∏ó‡∏µ‡∏¢‡∏ö
Prompt:

Translate the mechanism of action of Augmentin 625 Duo Tablet into English and keep it to one sentence.

| Role                                  | Example Output                                                                                                                                                                                                                                                                                                                                     |
| ------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| üß† **Teacher (GPT-4o-mini)**          | *‚ÄúAugmentin 625 Duo Tablet works by combining amoxicillin, a penicillin-type antibiotic that inhibits bacterial cell wall synthesis, with clavulanic acid, which protects amoxicillin from being broken down by beta-lactamase enzymes produced by certain bacteria, thereby enhancing the antibiotic's effectiveness against resistant strains.‚Äù* |
| üéì **Student (Fine-tuned Qwen-1.7B)** | *‚ÄúAugmentin 625 Duo Tablet is an antibiotic that combines Augmentin 625 (a third-generation cephalosporin) and Duo Tablet (a macrolide)...‚Äù*                                                                                                                                                                                                       |
| ‚öñÔ∏è **LLM Judge (GPT-4o-mini)**        | ‡∏ï‡∏±‡∏î‡∏™‡∏¥‡∏ô‡∏ß‡πà‡∏≤ **Teacher ‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤** ‡πÄ‡∏ô‡∏∑‡πà‡∏≠‡∏á‡∏à‡∏≤‡∏Å‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏Ç‡∏≠‡∏á‡∏Ñ‡∏£‡∏π‡∏ñ‡∏π‡∏Å‡∏ï‡πâ‡∏≠‡∏á‡∏ï‡∏≤‡∏°‡∏Ñ‡∏ß‡∏≤‡∏°‡∏à‡∏£‡∏¥‡∏á‡∏ó‡∏≤‡∏á‡πÄ‡∏†‡∏™‡∏±‡∏ä‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤ ‡∏™‡πà‡∏ß‡∏ô‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏Ç‡∏≠‡∏á‡∏ô‡∏±‡∏Å‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡∏£‡∏∞‡∏ö‡∏∏‡∏õ‡∏£‡∏∞‡πÄ‡∏†‡∏ó‡∏Ç‡∏≠‡∏á‡∏¢‡∏≤‡πÅ‡∏•‡∏∞‡∏Å‡∏•‡πÑ‡∏Å‡∏ú‡∏¥‡∏î‡∏û‡∏•‡∏≤‡∏î                                                                                                                                                                                                                 |
## üß† Conclusion and Discussion

‡∏Å‡∏≤‡∏£‡∏®‡∏∂‡∏Å‡∏©‡∏≤‡∏ô‡∏µ‡πâ‡∏°‡∏µ‡πÄ‡∏õ‡πâ‡∏≤‡∏´‡∏°‡∏≤‡∏¢‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏û‡∏±‡∏í‡∏ô‡∏≤‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏†‡∏≤‡∏©‡∏≤‡∏Ç‡∏ô‡∏≤‡∏î‡πÄ‡∏•‡πá‡∏Å (Qwen/Qwen3-1.7B) ‡πÉ‡∏´‡πâ‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏ó‡∏≥‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡πÅ‡∏•‡∏∞‡∏≠‡∏ò‡∏¥‡∏ö‡∏≤‡∏¢ ‡∏Å‡∏•‡πÑ‡∏Å‡∏Å‡∏≤‡∏£‡∏≠‡∏≠‡∏Å‡∏§‡∏ó‡∏ò‡∏¥‡πå‡∏Ç‡∏≠‡∏á‡∏¢‡∏≤ (Mechanism of Action) ‡∏£‡∏ß‡∏°‡∏ñ‡∏∂‡∏á ‡∏õ‡∏è‡∏¥‡∏Å‡∏¥‡∏£‡∏¥‡∏¢‡∏≤‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏¢‡∏≤ (Drug Interactions) ‡πÑ‡∏î‡πâ‡πÉ‡∏Å‡∏•‡πâ‡πÄ‡∏Ñ‡∏µ‡∏¢‡∏á‡∏Å‡∏±‡∏ö‡∏ú‡∏π‡πâ‡πÄ‡∏ä‡∏µ‡πà‡∏¢‡∏ß‡∏ä‡∏≤‡∏ç ‡πÇ‡∏î‡∏¢‡πÉ‡∏ä‡πâ‡∏Å‡∏£‡∏∞‡∏ö‡∏ß‡∏ô‡∏Å‡∏≤‡∏£ Teacher‚ÄìStudent Fine-Tuning ‡∏ã‡∏∂‡πà‡∏á‡πÉ‡∏´‡πâ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ç‡∏ô‡∏≤‡∏î‡πÉ‡∏´‡∏ç‡πà (GPT-4o-mini) ‡∏ó‡∏≥‡∏´‡∏ô‡πâ‡∏≤‡∏ó‡∏µ‡πà‡πÄ‡∏õ‡πá‡∏ô‡∏Ñ‡∏£‡∏π‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏Ñ‡∏∏‡∏ì‡∏†‡∏≤‡∏û‡∏™‡∏π‡∏á ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡πÉ‡∏ä‡πâ‡∏™‡∏≠‡∏ô‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏ô‡∏±‡∏Å‡πÄ‡∏£‡∏µ‡∏¢‡∏ô (Student Model)

‡∏ú‡∏•‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏û‡∏ö‡∏ß‡πà‡∏≤‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏ó‡∏µ‡πà‡∏ú‡πà‡∏≤‡∏ô‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏±‡∏ö‡∏à‡∏π‡∏ô‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡∏£‡∏π‡πâ‡∏Ñ‡∏≥‡∏®‡∏±‡∏û‡∏ó‡πå‡πÅ‡∏•‡∏∞‡∏Ñ‡∏≥‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡∏ó‡∏≤‡∏á‡∏ó‡∏≤‡∏á‡πÄ‡∏†‡∏™‡∏±‡∏ä‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤‡πÑ‡∏î‡πâ‡∏î‡∏µ‡∏û‡∏≠‡∏™‡∏°‡∏Ñ‡∏ß‡∏£ ‡πÅ‡∏ï‡πà‡∏¢‡∏±‡∏á‡∏°‡∏µ‡∏Ç‡πâ‡∏≠‡∏à‡∏≥‡∏Å‡∏±‡∏î‡πÉ‡∏ô‡∏î‡πâ‡∏≤‡∏ô‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ñ‡∏π‡∏Å‡∏ï‡πâ‡∏≠‡∏á‡πÄ‡∏ä‡∏¥‡∏á‡∏ï‡∏£‡∏£‡∏Å‡∏∞‡πÅ‡∏•‡∏∞‡∏Å‡∏≤‡∏£‡∏≠‡∏ò‡∏¥‡∏ö‡∏≤‡∏¢‡πÄ‡∏ä‡∏¥‡∏á‡πÄ‡∏´‡∏ï‡∏∏‡∏ú‡∏•‡∏ó‡∏≤‡∏á‡∏ä‡∏µ‡∏ß‡∏Å‡∏≤‡∏£‡πÅ‡∏û‡∏ó‡∏¢‡πå
‡πÇ‡∏î‡∏¢‡∏Ñ‡πà‡∏≤ BLEU (0.0097) ‡πÅ‡∏•‡∏∞ ROUGE-L (0.1060) ‡πÅ‡∏™‡∏î‡∏á‡∏ß‡πà‡∏≤‡πÇ‡∏Ñ‡∏£‡∏á‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏õ‡∏£‡∏∞‡πÇ‡∏¢‡∏Ñ‡∏Ç‡∏≠‡∏á‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏¢‡∏±‡∏á‡πÅ‡∏ï‡∏Å‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏≠‡πâ‡∏≤‡∏á‡∏≠‡∏¥‡∏á‡∏°‡∏≤‡∏Å ‡∏Ç‡∏ì‡∏∞‡∏ó‡∏µ‡πà Facet F1 (0.1861) ‡πÅ‡∏•‡∏∞ Fact Triple Match (0.05) ‡∏™‡∏∞‡∏ó‡πâ‡∏≠‡∏ô‡∏ß‡πà‡∏≤‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏ï‡∏£‡∏ß‡∏à‡∏à‡∏±‡∏ö‡∏≠‡∏á‡∏Ñ‡πå‡∏õ‡∏£‡∏∞‡∏Å‡∏≠‡∏ö‡∏û‡∏∑‡πâ‡∏ô‡∏ê‡∏≤‡∏ô ‡πÄ‡∏ä‡πà‡∏ô target, action, ‡πÅ‡∏•‡∏∞ pathway ‡πÑ‡∏î‡πâ‡∏ö‡∏≤‡∏á‡∏™‡πà‡∏ß‡∏ô ‡πÅ‡∏ï‡πà‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡πÄ‡∏ä‡∏∑‡πà‡∏≠‡∏°‡πÇ‡∏¢‡∏á‡∏Ñ‡∏ß‡∏≤‡∏°‡∏™‡∏±‡∏°‡∏û‡∏±‡∏ô‡∏ò‡πå ‚ÄúDrug‚ÄìAction‚ÄìTarget‚Äù ‡πÑ‡∏î‡πâ‡∏Ñ‡∏£‡∏ö‡∏ñ‡πâ‡∏ß‡∏ô
‡πÉ‡∏ô‡∏ó‡∏≤‡∏á‡∏Å‡∏•‡∏±‡∏ö‡∏Å‡∏±‡∏ô ‡∏Ñ‡πà‡∏≤ Key-Term Coverage (0.85) ‡πÅ‡∏™‡∏î‡∏á‡∏ß‡πà‡∏≤‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏à‡∏î‡∏à‡∏≥‡∏Ñ‡∏≥‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç ‡πÄ‡∏ä‡πà‡∏ô ‡∏ä‡∏∑‡πà‡∏≠‡πÄ‡∏≠‡∏ô‡πÑ‡∏ã‡∏°‡πå (CYP3A4), ‡∏ï‡∏±‡∏ß‡∏£‡∏±‡∏ö (receptor), ‡∏´‡∏£‡∏∑‡∏≠‡∏Å‡∏•‡∏∏‡πà‡∏°‡∏¢‡∏≤ (inhibitor, agonist) ‡πÑ‡∏î‡πâ‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á‡∏Ñ‡∏£‡∏ö ‡πÅ‡∏•‡∏∞‡∏Ñ‡πà‡∏≤ BERTScore-F1 (0.8381) ‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡∏Ñ‡∏ß‡∏≤‡∏°‡∏´‡∏°‡∏≤‡∏¢‡πÇ‡∏î‡∏¢‡∏£‡∏ß‡∏°‡∏Ç‡∏≠‡∏á‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏¢‡∏±‡∏á‡∏Ñ‡∏á‡πÉ‡∏Å‡∏•‡πâ‡πÄ‡∏Ñ‡∏µ‡∏¢‡∏á‡∏Å‡∏±‡∏ö‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏Ç‡∏≠‡∏á‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ñ‡∏£‡∏π‡πÉ‡∏ô‡∏£‡∏∞‡∏î‡∏±‡∏ö‡∏´‡∏ô‡∏∂‡πà‡∏á

‡∏≠‡∏¢‡πà‡∏≤‡∏á‡πÑ‡∏£‡∏Å‡πá‡∏ï‡∏≤‡∏° ‡∏Å‡∏≤‡∏£‡∏ó‡∏î‡∏™‡∏≠‡∏ö‡πÅ‡∏ö‡∏ö‡∏à‡∏±‡∏ö‡∏Ñ‡∏π‡πà‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö (Pairwise Preference Test) ‡∏û‡∏ö‡∏ß‡πà‡∏≤‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ñ‡∏£‡∏π‡πÉ‡∏´‡πâ‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏ó‡∏µ‡πà‡∏ñ‡∏π‡∏Å‡∏ï‡πâ‡∏≠‡∏á‡∏Å‡∏ß‡πà‡∏≤‡πÉ‡∏ô‡∏ó‡∏∏‡∏Å‡∏Å‡∏£‡∏ì‡∏µ (Teacher ‡∏ä‡∏ô‡∏∞ 100%) ‡∏ã‡∏∂‡πà‡∏á‡∏ä‡∏µ‡πâ‡πÉ‡∏´‡πâ‡πÄ‡∏´‡πá‡∏ô‡∏ß‡πà‡∏≤‡πÅ‡∏°‡πâ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏ô‡∏±‡∏Å‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡∏à‡∏∞‡∏ú‡πà‡∏≤‡∏ô‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏±‡∏ö‡∏à‡∏π‡∏ô‡πÅ‡∏•‡πâ‡∏ß ‡πÅ‡∏ï‡πà‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡πÄ‡∏•‡∏µ‡∏¢‡∏ô‡πÅ‡∏ö‡∏ö‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡πÄ‡∏ä‡∏¥‡∏á‡∏•‡∏∂‡∏Å‡πÅ‡∏•‡∏∞‡∏Ñ‡∏ß‡∏≤‡∏°‡∏ñ‡∏π‡∏Å‡∏ï‡πâ‡∏≠‡∏á‡∏ó‡∏≤‡∏á‡πÄ‡∏†‡∏™‡∏±‡∏ä‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤‡∏Ç‡∏≠‡∏á‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏Ñ‡∏£‡∏π‡πÑ‡∏î‡πâ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡πÄ‡∏ï‡πá‡∏°‡∏ó‡∏µ‡πà
‡∏™‡∏≤‡πÄ‡∏´‡∏ï‡∏∏‡∏´‡∏•‡∏±‡∏Å‡∏°‡∏≤‡∏à‡∏≤‡∏Å‡∏Ç‡πâ‡∏≠‡∏à‡∏≥‡∏Å‡∏±‡∏î‡∏î‡πâ‡∏≤‡∏ô‡∏Å‡∏≤‡∏£‡∏ù‡∏∂‡∏Å ‡πÑ‡∏î‡πâ‡πÅ‡∏Å‡πà

1) ‡∏Ñ‡πà‡∏≤‡∏û‡∏≤‡∏£‡∏≤‡∏°‡∏¥‡πÄ‡∏ï‡∏≠‡∏£‡πå LoRA ‡∏ó‡∏µ‡πà‡∏ï‡πà‡∏≥ (r=8) ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡∏£‡∏π‡πâ pattern ‡∏ó‡∏µ‡πà‡∏ã‡∏±‡∏ö‡∏ã‡πâ‡∏≠‡∏ô‡πÑ‡∏î‡πâ‡πÑ‡∏°‡πà‡∏°‡∏≤‡∏Å‡∏û‡∏≠

2) ‡∏£‡∏π‡∏õ‡πÅ‡∏ö‡∏ö‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏Ç‡∏≠‡∏á‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡∏ù‡∏∂‡∏Å‡πÑ‡∏°‡πà‡∏™‡∏°‡πà‡∏≥‡πÄ‡∏™‡∏°‡∏≠ ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏ï‡∏≠‡∏ö‡πÑ‡∏î‡πâ‡πÑ‡∏°‡πà‡∏ï‡∏£‡∏á‡∏ï‡∏≤‡∏°‡πÇ‡∏à‡∏ó‡∏¢‡πå‡∏´‡∏£‡∏∑‡∏≠‡∏¢‡∏∑‡∏î‡∏¢‡∏≤‡∏ß‡πÄ‡∏Å‡∏¥‡∏ô‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô

3) ‡∏Ç‡∏≤‡∏î‡∏Å‡∏£‡∏∞‡∏ö‡∏ß‡∏ô‡∏Å‡∏≤‡∏£‡∏ù‡∏∂‡∏Å‡πÅ‡∏ö‡∏ö Preference Optimization (‡πÄ‡∏ä‡πà‡∏ô DPO) ‡∏ó‡∏µ‡πà‡∏ä‡πà‡∏ß‡∏¢‡πÉ‡∏´‡πâ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡πÄ‡∏£‡∏µ‡∏¢‡∏ô‡∏£‡∏π‡πâ‡∏Ñ‡∏ß‡∏≤‡∏°‡πÅ‡∏ï‡∏Å‡∏ï‡πà‡∏≤‡∏á‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏ó‡∏µ‡πà‡∏î‡∏µ‡πÅ‡∏•‡∏∞‡πÑ‡∏°‡πà‡∏î‡∏µ

‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏ï‡πà‡∏≠‡∏¢‡∏≠‡∏î‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏î‡∏•‡∏≠‡∏á‡∏ô‡∏µ‡πâ ‡∏Ñ‡∏ß‡∏£‡∏õ‡∏£‡∏±‡∏ö‡∏õ‡∏£‡∏∏‡∏á‡πÉ‡∏ô‡∏´‡∏•‡∏≤‡∏¢‡∏î‡πâ‡∏≤‡∏ô ‡πÑ‡∏î‡πâ‡πÅ‡∏Å‡πà

- ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏õ‡∏£‡∏∞‡∏™‡∏¥‡∏ó‡∏ò‡∏¥‡∏†‡∏≤‡∏û‡∏Ç‡∏≠‡∏á LoRA ‡πÇ‡∏î‡∏¢‡∏Ç‡∏¢‡∏≤‡∏¢‡∏Ñ‡πà‡∏≤ rank ‡πÅ‡∏•‡∏∞‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏à‡∏≥‡∏ô‡∏ß‡∏ô‡πÄ‡∏•‡πÄ‡∏¢‡∏≠‡∏£‡πå‡∏ó‡∏µ‡πà‡∏õ‡∏£‡∏±‡∏ö‡πÑ‡∏î‡πâ

- ‡∏Å‡∏≥‡∏´‡∏ô‡∏î‡∏£‡∏π‡∏õ‡πÅ‡∏ö‡∏ö‡∏Ç‡∏≠‡∏á prompt ‡πÅ‡∏•‡∏∞‡∏£‡∏π‡∏õ‡πÅ‡∏ö‡∏ö‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡πÉ‡∏´‡πâ‡∏ä‡∏±‡∏î‡πÄ‡∏à‡∏ô‡∏°‡∏≤‡∏Å‡∏Ç‡∏∂‡πâ‡∏ô ‡πÄ‡∏ä‡πà‡∏ô ‡∏Å‡∏≤‡∏£‡∏ï‡∏≠‡∏ö‡πÄ‡∏õ‡πá‡∏ô‡∏õ‡∏£‡∏∞‡πÇ‡∏¢‡∏Ñ‡πÄ‡∏î‡∏µ‡∏¢‡∏ß‡∏û‡∏£‡πâ‡∏≠‡∏°‡πÇ‡∏Ñ‡∏£‡∏á ‚ÄúDrug‚ÄìAction‚ÄìTarget‚Äù

- ‡∏Ç‡∏¢‡∏≤‡∏¢‡∏ê‡∏≤‡∏ô‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡∏Ñ‡∏≥‡∏®‡∏±‡∏û‡∏ó‡πå‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡∏ó‡∏≤‡∏á (domain lexicon) ‡πÄ‡∏ä‡πà‡∏ô ‡∏ä‡∏∑‡πà‡∏≠‡πÄ‡∏≠‡∏ô‡πÑ‡∏ã‡∏°‡πå ‡∏ï‡∏±‡∏ß‡∏£‡∏±‡∏ö ‡πÅ‡∏•‡∏∞‡∏Å‡∏•‡πÑ‡∏Å‡∏Å‡∏≤‡∏£‡∏≠‡∏≠‡∏Å‡∏§‡∏ó‡∏ò‡∏¥‡πå

- ‡∏ó‡∏î‡∏•‡∏≠‡∏á‡πÉ‡∏ä‡πâ‡∏ß‡∏¥‡∏ò‡∏µ Direct Preference Optimization (DPO) ‡∏´‡∏£‡∏∑‡∏≠‡πÄ‡∏ó‡∏Ñ‡∏ô‡∏¥‡∏Ñ reinforcement-based fine-tuning ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡πÉ‡∏´‡πâ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡πÅ‡∏¢‡∏Å‡πÅ‡∏¢‡∏∞‡∏Ñ‡∏≥‡∏ï‡∏≠‡∏ö‡∏ó‡∏µ‡πà‡∏ñ‡∏π‡∏Å‡∏ï‡πâ‡∏≠‡∏á‡πÅ‡∏•‡∏∞‡πÉ‡∏´‡πâ‡πÄ‡∏´‡∏ï‡∏∏‡∏ú‡∏•‡πÑ‡∏î‡πâ‡∏î‡∏µ‡∏¢‡∏¥‡πà‡∏á‡∏Ç‡∏∂‡πâ‡∏ô

- ‡πÄ‡∏Å‡πá‡∏ö‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏• Perplexity (PPL) ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏ù‡∏∂‡∏Å‡∏Ñ‡∏£‡∏±‡πâ‡∏á‡∏ï‡πà‡∏≠‡πÑ‡∏õ ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏Ñ‡∏ß‡∏≤‡∏°‡∏•‡∏∑‡πà‡∏ô‡πÑ‡∏´‡∏•‡πÅ‡∏•‡∏∞‡∏Ñ‡∏ß‡∏≤‡∏°‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡∏Ç‡∏≠‡∏á‡∏Å‡∏≤‡∏£ overfitting

‡πÇ‡∏î‡∏¢‡∏™‡∏£‡∏∏‡∏õ ‡∏Å‡∏≤‡∏£‡∏ó‡∏î‡∏•‡∏≠‡∏á‡∏ô‡∏µ‡πâ‡πÅ‡∏™‡∏î‡∏á‡πÉ‡∏´‡πâ‡πÄ‡∏´‡πá‡∏ô‡∏ß‡πà‡∏≤ ‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏±‡∏ö‡∏à‡∏π‡∏ô‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏†‡∏≤‡∏©‡∏≤‡∏Ç‡∏ô‡∏≤‡∏î‡πÄ‡∏•‡πá‡∏Å (Sub-4B) ‡∏î‡πâ‡∏ß‡∏¢‡πÅ‡∏ô‡∏ß‡∏ó‡∏≤‡∏á Teacher‚ÄìStudent Fine-Tuning ‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏ó‡∏≥‡πÑ‡∏î‡πâ‡∏à‡∏£‡∏¥‡∏á‡∏†‡∏≤‡∏¢‡πÉ‡∏ï‡πâ‡∏ó‡∏£‡∏±‡∏û‡∏¢‡∏≤‡∏Å‡∏£‡∏à‡∏≥‡∏Å‡∏±‡∏î (GPU L4 ‡∏ö‡∏ô Google Colab) ‡πÅ‡∏•‡∏∞‡∏°‡∏µ‡∏®‡∏±‡∏Å‡∏¢‡∏†‡∏≤‡∏û‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏õ‡∏£‡∏∞‡∏¢‡∏∏‡∏Å‡∏ï‡πå‡πÉ‡∏ä‡πâ‡∏Å‡∏±‡∏ö‡∏á‡∏≤‡∏ô‡∏î‡πâ‡∏≤‡∏ô‡πÄ‡∏†‡∏™‡∏±‡∏ä‡∏ß‡∏¥‡∏ó‡∏¢‡∏≤
‡πÅ‡∏°‡πâ‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏ó‡∏µ‡πà‡πÑ‡∏î‡πâ‡∏à‡∏∞‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡πÅ‡∏ó‡∏ô‡∏ó‡∏µ‡πà‡∏ú‡∏π‡πâ‡πÄ‡∏ä‡∏µ‡πà‡∏¢‡∏ß‡∏ä‡∏≤‡∏ç‡πÑ‡∏î‡πâ‡πÉ‡∏ô‡∏õ‡∏±‡∏à‡∏à‡∏∏‡∏ö‡∏±‡∏ô ‡πÅ‡∏ï‡πà‡∏ú‡∏•‡∏Å‡∏≤‡∏£‡∏ó‡∏î‡∏•‡∏≠‡∏á‡∏ä‡∏µ‡πâ‡πÉ‡∏´‡πâ‡πÄ‡∏´‡πá‡∏ô‡∏ó‡∏¥‡∏®‡∏ó‡∏≤‡∏á‡∏ó‡∏µ‡πà‡∏ä‡∏±‡∏î‡πÄ‡∏à‡∏ô‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡∏û‡∏±‡∏í‡∏ô‡∏≤‡πÇ‡∏°‡πÄ‡∏î‡∏•‡∏†‡∏≤‡∏©‡∏≤‡∏Ç‡∏ô‡∏≤‡∏î‡πÄ‡∏•‡πá‡∏Å‡πÉ‡∏´‡πâ‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡πÄ‡∏Ç‡πâ‡∏≤‡πÉ‡∏à‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•‡πÄ‡∏ä‡∏¥‡∏á‡∏Å‡∏≤‡∏£‡πÅ‡∏û‡∏ó‡∏¢‡πå‡πÑ‡∏î‡πâ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏•‡∏∂‡∏Å‡∏ã‡∏∂‡πâ‡∏á‡∏¢‡∏¥‡πà‡∏á‡∏Ç‡∏∂‡πâ‡∏ô‡πÉ‡∏ô‡∏≠‡∏ô‡∏≤‡∏Ñ‡∏ï
